FY2026 EPS Estimates for MariMed Raised by Noble Financial

MariMed Inc. (OTCMKTS:MRMD) – Equities research analysts at Noble Financial raised their FY2026 earnings estimates for shares of MariMed in a report released on Friday, May 15th. Noble Financial analyst J. Gomes now forecasts that the company will post earnings of ($0.04) per share for the year, up from their previous forecast of ($0.05). The consensus estimate for MariMed’s current full-year earnings is ($0.05) per share. Noble Financial also issued estimates for MariMed’s Q4 2026 earnings at ($0.03) EPS.

MariMed Trading Up 7.4%

Shares of OTCMKTS:MRMD opened at $0.07 on Tuesday. The company’s 50-day moving average price is $0.08 and its two-hundred day moving average price is $0.09. The company has a debt-to-equity ratio of 1.67, a current ratio of 0.95 and a quick ratio of 0.34. MariMed has a one year low of $0.06 and a one year high of $0.23. The stock has a market capitalization of $28.54 million, a PE ratio of -2.38 and a beta of 1.33.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). MariMed had a negative net margin of 7.82% and a negative return on equity of 5.00%. The firm had revenue of $39.48 million for the quarter, compared to analysts’ expectations of $38.75 million.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.